 | • レポートコード：QY20ST-05429 • 出版社/出版日：QYResearch / 2020年9月15日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、137ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥560,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥840,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,120,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、世界の疾患修飾性抗リウマチ薬市場について種類別（非ステロイド性抗炎症薬、ステロイド性抗炎症薬、遅効性薬、免疫学的製剤）、用途別（製薬産業、病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・疾患修飾性抗リウマチ薬市場の概要 ・世界の主要地域別疾患修飾性抗リウマチ薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の疾患修飾性抗リウマチ薬市場規模2015-2026：種類別（非ステロイド性抗炎症薬、ステロイド性抗炎症薬、遅効性薬、免疫学的製剤） ・世界の疾患修飾性抗リウマチ薬市場規模2015-2026：用途別（製薬産業、病院、クリニック、その他） ・疾患修飾性抗リウマチ薬の北米市場規模2015-2020 ・疾患修飾性抗リウマチ薬のヨーロッパ市場規模2015-2020 ・疾患修飾性抗リウマチ薬の中国市場規模2015-2020 ・疾患修飾性抗リウマチ薬の日本市場規模2015-2020 ・疾患修飾性抗リウマチ薬の東南アジア市場規模2015-2020 ・疾患修飾性抗リウマチ薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・疾患修飾性抗リウマチ薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・疾患修飾性抗リウマチ薬の市場動向・機会・課題 ・調査の結論 |
A recently published report by QY Research titled Global Disease-Modifying Antirheumatic Drug Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Disease-Modifying Antirheumatic Drug market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
It refers to drugs that can treat rheumatism, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, etc.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Disease-Modifying Antirheumatic Drug market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Disease-Modifying Antirheumatic Drug industry.
Based on our recent survey, we have several different scenarios about the Disease-Modifying Antirheumatic Drug YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Disease-Modifying Antirheumatic Drug will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Disease-Modifying Antirheumatic Drug market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Disease-Modifying Antirheumatic Drug market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Disease-Modifying Antirheumatic Drug market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Disease-Modifying Antirheumatic Drug market. The report also includes nautical information, where it shows Disease-Modifying Antirheumatic Drug market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Disease-Modifying Antirheumatic Drug market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Disease-Modifying Antirheumatic Drug market.
Geographical Analysis:
Based on region, the global Disease-Modifying Antirheumatic Drug market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Disease-Modifying Antirheumatic Drug market are
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
Segment by Application
Pharmaceutical Industry
Hospital and Clinic
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Disease-Modifying Antirheumatic Drug market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Disease-Modifying Antirheumatic Drug market.
• The market share of the global Disease-Modifying Antirheumatic Drug market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Disease-Modifying Antirheumatic Drug market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Disease-Modifying Antirheumatic Drug market.
1 Disease-Modifying Antirheumatic Drug Market Overview
1.1 Disease-Modifying Antirheumatic Drug Product Scope
1.2 Disease-Modifying Antirheumatic Drug Segment by Type
1.2.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2020-2026)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Disease-Modifying Antirheumatic Drug Segment by Application
1.3.1 Global Disease-Modifying Antirheumatic Drug Sales Comparison by Application (2020-2026)
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2026)
1.4.2 Global Disease-Modifying Antirheumatic Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Disease-Modifying Antirheumatic Drug Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Disease-Modifying Antirheumatic Drug Industry Impact
1.5.1 How the Covid-19 is Affecting the Disease-Modifying Antirheumatic Drug Industry
1.5.1.1 Disease-Modifying Antirheumatic Drug Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Disease-Modifying Antirheumatic Drug Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
2 Disease-Modifying Antirheumatic Drug Estimate and Forecast by Region
2.1 Global Disease-Modifying Antirheumatic Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020)
2.3 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Disease-Modifying Antirheumatic Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
2.4.2 Europe Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
2.4.3 China Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
2.4.4 Japan Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
2.4.6 India Disease-Modifying Antirheumatic Drug Estimates and Projections (2015-2026)
3 Global Disease-Modifying Antirheumatic Drug Competition Landscape by Players
3.1 Global Top Disease-Modifying Antirheumatic Drug Players by Sales (2015-2020)
3.2 Global Top Disease-Modifying Antirheumatic Drug Players by Revenue (2015-2020)
3.3 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2019)
3.4 Global Disease-Modifying Antirheumatic Drug Average Price by Company (2015-2020)
3.5 Manufacturers Disease-Modifying Antirheumatic Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Disease-Modifying Antirheumatic Drug Players (Opinion Leaders)
4 Global Disease-Modifying Antirheumatic Drug Market Size by Type
4.1 Global Disease-Modifying Antirheumatic Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2014-2020)
4.2 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Type (2021-2026)
5 Global Disease-Modifying Antirheumatic Drug Market Size by Application
5.1 Global Disease-Modifying Antirheumatic Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2015-2020)
5.2 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2021-2026)
3 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures
3.2 North America Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
3.3 North America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
3.4 North America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
4 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures
4.2 Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
4.3 Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
4.4 Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
5 China Disease-Modifying Antirheumatic Drug Market Facts & Figures
5.2 China Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
5.3 China Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
5.4 China Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
6 Japan Disease-Modifying Antirheumatic Drug Market Facts & Figures
6.2 Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
6.3 Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
6.4 Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
7 Southeast Asia Disease-Modifying Antirheumatic Drug Market Facts & Figures
7.2 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
8 India Disease-Modifying Antirheumatic Drug Market Facts & Figures
8.2 India Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
8.3 India Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
8.4 India Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Disease-Modifying Antirheumatic Drug Business
12.1 AbbVie
12.1.1 AbbVie Disease-Modifying Antirheumatic Drug Corporation Information
12.1.2 AbbVie Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
12.1.5 AbbVie Recent Development
12.2 Amgen
12.2.1 Amgen Disease-Modifying Antirheumatic Drug Corporation Information
12.2.2 Amgen Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Amgen Disease-Modifying Antirheumatic Drug Products Offered
12.2.5 Amgen Recent Development
12.3 Pfizer
12.3.1 Pfizer Disease-Modifying Antirheumatic Drug Corporation Information
12.3.2 Pfizer Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Pfizer Disease-Modifying Antirheumatic Drug Products Offered
12.3.5 Pfizer Recent Development
12.4 Roche Holding AG
12.4.1 Roche Holding AG Disease-Modifying Antirheumatic Drug Corporation Information
12.4.2 Roche Holding AG Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Products Offered
12.4.5 Roche Holding AG Recent Development
12.5 Novartis International AG
12.5.1 Novartis International AG Disease-Modifying Antirheumatic Drug Corporation Information
12.5.2 Novartis International AG Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Products Offered
12.5.5 Novartis International AG Recent Development
12.6 Johnson & Johnson
12.6.1 Johnson & Johnson Disease-Modifying Antirheumatic Drug Corporation Information
12.6.2 Johnson & Johnson Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Products Offered
12.6.5 Johnson & Johnson Recent Development
12.7 Bristol-Myers Squibb
12.7.1 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Corporation Information
12.7.2 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Products Offered
12.7.5 Bristol-Myers Squibb Recent Development
12.8 Merck
12.8.1 Merck Disease-Modifying Antirheumatic Drug Corporation Information
12.8.2 Merck Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Merck Disease-Modifying Antirheumatic Drug Products Offered
12.8.5 Merck Recent Development
12.9 UCB S.A.
12.9.1 UCB S.A. Disease-Modifying Antirheumatic Drug Corporation Information
12.9.2 UCB S.A. Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Products Offered
12.9.5 UCB S.A. Recent Development
12.10 Eli Lilly and Company
12.10.1 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Corporation Information
12.10.2 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Business Overview and Total Revenue
12.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Products Offered
12.10.5 Eli Lilly and Company Recent Development
13 Disease-Modifying Antirheumatic Drug Manufacturing Cost Analysis
13.1 Disease-Modifying Antirheumatic Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
13.4 Disease-Modifying Antirheumatic Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Disease-Modifying Antirheumatic Drug Distributors List
14.3 Disease-Modifying Antirheumatic Drug Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Disease-Modifying Antirheumatic Drug Sales (MT) Growth Rate by Type (2020-2026)
Table 2. Global Disease-Modifying Antirheumatic Drug Sales (MT) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Disease-Modifying Antirheumatic Drug Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Disease-Modifying Antirheumatic Drug Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
Table 8. Global Market Disease-Modifying Antirheumatic Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Region (2015-2020)
Table 10. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
Table 11. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Disease-Modifying Antirheumatic Drug Revenue Share by Region (2015-2020)
Table 13. Global Disease-Modifying Antirheumatic Drug Sales (MT) Forecast by Region (2021-2026)
Table 14. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Disease-Modifying Antirheumatic Drug Revenue Share Forecast by Region (2021-2026)
Table 17. Global Disease-Modifying Antirheumatic Drug (MT) of Key Companies (2015-2020)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales Share by Company (2015-2020)
Table 19. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Disease-Modifying Antirheumatic Drug Revenue Share by Company (2015-2020)
Table 21. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2019)
Table 22. Global Disease-Modifying Antirheumatic Drug Average Price (USD/MT) of Key Company (2015-2020)
Table 23. Manufacturers Disease-Modifying Antirheumatic Drug Manufacturing Sites and Area Served
Table 24. Manufacturers Disease-Modifying Antirheumatic Drug Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Disease-Modifying Antirheumatic Drug Players
Table 27. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 28. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2015-2020)
Table 29. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Disease-Modifying Antirheumatic Drug Price (MT) by Type (2015-2020)
Table 31. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2021-2026)
Table 32. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2021-2026)
Table 34. Global Disease-Modifying Antirheumatic Drug Price (MT) by Type (2021-2026)
Table 35. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 36. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2015-2020)
Table 37. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Disease-Modifying Antirheumatic Drug Price (MT) by Application (2015-2020)
Table 39. Global Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2021-2026)
Table 40. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2021-2026)
Table 41. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Disease-Modifying Antirheumatic Drug Revenue Share by Application (2021-2026)
Table 43. Global Disease-Modifying Antirheumatic Drug Price (MT) by Application (2021-2026)
Table 44. United States Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 45. United States Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 46. United States Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 47. United States Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 48. United States Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 49. United States Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 50. Europe Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 51. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 52. Europe Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 53. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 54. Europe Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 55. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 56. China Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 57. China Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 58. China Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 59. China Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 60. China Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 61. China Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 62. Japan Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 63. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 64. Japan Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 65. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 66. Japan Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 67. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 69. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 71. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 73. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 74. India Disease-Modifying Antirheumatic Drug Sales (MT) by Company (2015-2020)
Table 75. India Disease-Modifying Antirheumatic Drug Sales Market Share by Company (2015-2020)
Table 76. India Disease-Modifying Antirheumatic Drug Sales (MT) by Type (2015-2020)
Table 77. India Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 78. India Disease-Modifying Antirheumatic Drug Sales (MT) by Application (2015-2020)
Table 79. India Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 80. AbbVie Corporation Information
Table 81. AbbVie Description and Business Overview
Table 82. AbbVie Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. AbbVie Disease-Modifying Antirheumatic Drug Product
Table 84. AbbVie Recent Development
Table 85. Amgen Corporation Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Amgen Disease-Modifying Antirheumatic Drug Product
Table 89. Amgen Recent Development
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Pfizer Disease-Modifying Antirheumatic Drug Product
Table 94. Pfizer Recent Development
Table 95. Roche Holding AG Corporation Information
Table 96. Roche Holding AG Description and Business Overview
Table 97. Roche Holding AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Roche Holding AG Disease-Modifying Antirheumatic Drug Product
Table 99. Roche Holding AG Recent Development
Table 100. Novartis International AG Corporation Information
Table 101. Novartis International AG Description and Business Overview
Table 102. Novartis International AG Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Novartis International AG Disease-Modifying Antirheumatic Drug Product
Table 104. Novartis International AG Recent Development
Table 105. Johnson & Johnson Corporation Information
Table 106. Johnson & Johnson Description and Business Overview
Table 107. Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Johnson & Johnson Disease-Modifying Antirheumatic Drug Product
Table 109. Johnson & Johnson Recent Development
Table 110. Bristol-Myers Squibb Corporation Information
Table 111. Bristol-Myers Squibb Description and Business Overview
Table 112. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 113. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product
Table 114. Bristol-Myers Squibb Recent Development
Table 115. Merck Corporation Information
Table 116. Merck Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Merck Description and Business Overview
Table 118. Merck Disease-Modifying Antirheumatic Drug Product
Table 119. Merck Recent Development
Table 120. UCB S.A. Corporation Information
Table 121. UCB S.A. Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. UCB S.A. Description and Business Overview
Table 123. UCB S.A. Disease-Modifying Antirheumatic Drug Product
Table 124. UCB S.A. Recent Development
Table . Eli Lilly and Company Corporation Information
Table . Eli Lilly and Company Description and Business Overview
Table . Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table . Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product
Table . Eli Lilly and Company Recent Development
Table 130. Production Base and Market Concentration Rate of Raw Material
Table 131. Key Suppliers of Raw Materials
Table 132. Disease-Modifying Antirheumatic Drug Distributors List
Table 133. Disease-Modifying Antirheumatic Drug Customers List
Table 134. Market Key Trends
Table 135. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 136. Key Challenges
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Disease-Modifying Antirheumatic Drug Product Picture
Figure 2. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Disease-Modifying Antirheumatic Drug Market Share by Application in 2020 & 2026
Figure 6. Pharmaceutical Industry Examples
Figure 7. Hospital and Clinic Examples
Figure 8. Other Examples
Figure 9. Global Disease-Modifying Antirheumatic Drug Sales (MT) Growth Rate (2015-2026)
Figure 10. Global Disease-Modifying Antirheumatic Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Disease-Modifying Antirheumatic Drug Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 12. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Disease-Modifying Antirheumatic Drug Sales (MT) Growth Rate (2015-2026)
Figure 16. Europe Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Disease-Modifying Antirheumatic Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Disease-Modifying Antirheumatic Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Disease-Modifying Antirheumatic Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Disease-Modifying Antirheumatic Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Disease-Modifying Antirheumatic Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Disease-Modifying Antirheumatic Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Disease-Modifying Antirheumatic Drug Players Market Share by Revenue in Disease-Modifying Antirheumatic Drug 2015 & 2019
Figure 27. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2015-2020)
Figure 29. Global Disease-Modifying Antirheumatic Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Disease-Modifying Antirheumatic Drug Revenue Share by Application (2015-2020)
Figure 31. Global Disease-Modifying Antirheumatic Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 33. United States Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 34. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2019
Figure 35. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 36. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 37. China Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2019
Figure 38. China Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 39. China Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 40. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2019
Figure 41. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 42. Japan Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 46. India Disease-Modifying Antirheumatic Drug Sales Market Share by Company in 2019
Figure 47. India Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 48. India Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 49. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Novartis International AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. UCB S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Key Raw Materials Price Trend
Figure 60. Manufacturing Cost Structure of Disease-Modifying Antirheumatic Drug
Figure 61. Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
Figure 62. Disease-Modifying Antirheumatic Drug Industrial Chain Analysis
Figure 63. Channels of Distribution
Figure 64. Distributors Profiles
Figure 65. Porter's Five Forces Analysis
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
抗エイズ薬の世界市場レポート2020 A recently published report by QY Research titled Global Anti-AIDs Drug Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate dat…- 緑内障治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Anti-glaucoma Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anti-glaucoma Drug market …
- 抗腫瘍薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Anti-tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
- 自己免疫疾患治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Autoimmune Disease Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 喘息・COPD薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Asthma and COPD Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.2% in the forecast period of 2020 to 2025 and will expected to reach USD 14200 million by 2025, from USD 13000 million in 2019. The Asthma and COPD D…